Skip to main navigation

About
- - Leadership team
  - Careers
Our Work
Investors

Contact

Press releases

Press Releases
Events
Presentations

Year

March 24, 2026

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst

March 17, 2026

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation

March 10, 2026

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

March 6, 2026

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

March 3, 2026

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression

February 26, 2026

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

February 20, 2026

AtaiBeckley To Host Virtual Investor Day on March 6, 2026

February 19, 2026

AtaiBeckley Appoints Michael Faerm as Chief Financial Officer

February 17, 2026

AtaiBeckley To Participate in Upcoming Investor Conferences

January 16, 2026

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

Current page 1
Page 2
Page 3
…
Next page
Last page

Displaying 1 - 10 of 169

Click here to join the AtaiBeckley newsletter

Careers
Privacy Statement
Cookie Policy

© 2026 AtaiBeckley Inc., All Rights Reserved